Grifols | GRFS - Selling And Administration Expenses


Grifols reported EUR320.45M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 447K 138K Mar/2026
Arca Biopharma USD 2.23M 1.08M Dec/2025
aTyr Pharma USD 700.63K 81.56M Mar/2026
Bio Path USD 259K 60K Mar/2026
Brainstorm Cell Therapeutics USD 1.21M 178K Mar/2026
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Cara Therapeutics USD 2.09M 96K Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Grifols EUR 320.45M 12.65M Dec/2025
Immunic USD 3.45M 451K Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
TherapeuticsMD USD 1.23M 90K Jun/2024